Longeveron IncChange company Symbol lookupSelect an option...LGVN Longeveron IncCRK Comstock Resources IncFLS Flowserve CorpCWBR CohBar IncNRT North European Oil Royalty TrustLTC LTC Properties IncBAC Bank of America CorpENVB Enveric Biosciences IncBKE Buckle IncROP Roper Technologies IncGo
Change company Symbol lookup
Select an option...
LGVN Longeveron Inc
CRK Comstock Resources Inc
FLS Flowserve Corp
CWBR CohBar Inc
NRT North European Oil Royalty Trust
LTC LTC Properties Inc
BAC Bank of America Corp
ENVB Enveric Biosciences Inc
BKE Buckle Inc
ROP Roper Technologies Inc
Health Care : Biotechnology | Small Cap Value
Company profileLongeveron Inc. is a clinical-stage biotechnology company, which is developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, such as aging related frailty, Alzheimer's disease (AD), acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.
|
|
|
|
| |
| Annual Earnings Missed Consensus (Year ending 12/2022) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Annual Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced March 10, 2023 | -$0.90 | Annual Consensus of 2 analysts | -$0.84 | Difference from consensus | -7.14% | 2023 Earnings will announce | (Unconfirmed) August 11, 2023 |
Annual Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
LGVN's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.